Patent: 10,870,695
✉ Email this page to a colleague
Summary for Patent: 10,870,695
| Title: | Biopharmaceutical compositions comprising interleukin-5 antibody |
| Abstract: | The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods. |
| Inventor(s): | Myrna A. Monck, Narendra B. BAM, Jennifer DALLY, Michelle SPATARA |
| Assignee: | GlaxoSmithKline Intellectual Property No 2 Ltd |
| Application Number: | US15/754,768 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,870,695
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | NUCALA | mepolizumab | For Injection | 125526 | 4-Nov-15 | 10,870,695 | 2036-08-22 |
| Glaxosmithkline Llc | NUCALA | mepolizumab | Injection | 125526 | 6-Jun-19 | 10,870,695 | 2036-08-22 |
| Glaxosmithkline Llc | NUCALA | mepolizumab | Injection | 125526 | 22-Jan-22 | 10,870,695 | 2036-08-22 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,870,695
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Argentina | 105794 | ⤷ Start Trial |
| Australia | 2016311385 | ⤷ Start Trial |
| Brazil | 112018003741 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
